Skip to main content
Premium Trial:

Request an Annual Quote

Empiriko, Interchim Partner on Mass Spec-based Drug Metabolism Research

NEW YORK (GenomeWeb News) – Empiriko will use Interchim's mass spectrometry-based technology to perform drug metabolism studies as part of a partnership between the companies announced today.

Under the terms of the deal, Empiriko will leverage Interchim's PuriFlash MassSpec technology to perform near real-time and cost-effective in vitro and ex vivo studies using Empiriko's Biomimiks technology.

The BioMimiks technology consists of in vitro and ex vivo biomimetic systems that serve as "chemosynthetic livers" to generate and predict metabolic profiles of drugs. The PuriFlash instruments include mass spectrometry for near real-time product separation and structural elucidation of purified compounds.

By leveraging each firm's technologies and expertise, drug developers will be able to predict metabolism patterns, pathways, and profiles, and generate "a complete spectrum of oxidative metabolites for specific drugs … reducing the time for each experiment from weeks to hours," Empiriko and Interchim said.

Researchers will additionally be able to rapidly identify interactions involving metabolite attenuation and suppression, and "evaluate the genotoxicity, drug-to-drug interactions, and efficacy associated with adding a new drug to a patient's drug regimen."

As part of the deal, Empiriko will also provide input to Interchim on the design of future instrumentation for ex vivo studies aimed at personalized patient treatment. Financial and other terms were not disclosed.

"Together we will accelerate the delineation of metabolism profiles, enable prediction and scale-up of products, and offer scientists a valuable tool for rapid separation and quantification of products," Empiriko CSO Mukund Chorghade said in a statement.

Based in Newton, Mass., Empiriko calls itself a "clinical intelligence company" that leverages chemistry-based research and in silico modeling for drug discovery and development.

Interchim, headquartered in France and with a US office in Los Angeles, manufactures and distributes instruments, products, and consumables to the research community and to industry.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.